[ad_1]
Chicago, April 5, 2024–(BUSINESS WIRE)–MAIA Biotechnology, Inc. (NYSE: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced its Chairman and Chief Executive Officer Vlad Vitoc, MD, will present at two investor conferences in April: the 14th Annual LD Micro Invitational on April 8-9, 2024 in New York City; Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference.
LD micro:
Promotional meeting: |
April 9, 2024 04:30 PM EST* |
Format: |
In-person and virtual |
Place: |
Sofitel New York, New York City |
Conference registration: |
Visit the conference website |
Live broadcast registration: |
Visit Sequire events |
1×1 meeting: |
According to the requirements of registered investors |
Noble capital market:
Promotional meeting: |
April 17, 2024, 11:00 AM ET* |
Format: |
Virtual |
Conference registration: |
Visit the conference website |
1×1 meeting: |
According to the requirements of registered investors |
*Please note that demonstration dates and times are subject to change. Participants should refer to the final program agenda for the latest information.
MAIA’s lead drug candidate is THIO, a small molecule telomere-targeted anticancer agent that works by producing direct telomeric DNA damage and inducing a cancer-specific immune response. The efficacy of THIO in non-small cell lung cancer (NSCLC) is being evaluated in THIO-101, a Phase 2 marketing clinical trial that is about to be completed and is expected to be the first completed clinical study of a telomere-targeted drug. The field of cancer drug discovery and treatment. MAIA plans to seek accelerated approval from the FDA for THIO.
Latest news from MAIA’s THIO-101 trial include:
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potentially first-in-class medicines with novel mechanisms of action designed to meaningfully improve and extend the lives of cancer patients. Our lead program is THIO, a potential first-in-class cancer telomere-targeting agent in clinical development for the treatment of NSCLC patients harboring telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
forward-looking statements
MAIA cautions that all statements, other than statements of historical fact contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels or activities, performance or achievements to be materially different from those anticipated by such statements. Use words such as “may,” “could,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project” and “intend” , “future,” “potential” or “continue” and other similar expressions are intended to identify forward-looking statements. However, the absence of these words does not mean that these statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) the advancement and successful completion of our product candidates into clinical capability studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and improve manufacturing processes, (v) market acceptance of our product candidates and The extent, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward-looking of. All forward-looking statements are based on our management’s current estimates, assumptions and expectations, which, although we believe are reasonable, are inherently uncertain. Any forward-looking statements that express expectations or beliefs about future events are expressed in good faith and were believed to be reasonable at the time such forward-looking statements were made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that could cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it is made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In this press release, unless the context otherwise requires, “MAIA”, “the Company”, “we”, “us” and “our” refer to MAIA Biotechnology, Inc. and its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240405374193/en/
contact method
Investor Relations Contact Information
+1 (872) 270-3518
ir@maiabiotech.com
[ad_2]
Source link